

Special Issue

Challenges and Therapeutic Prospects in Hematology Oncology

Message from the Guest Editor

Hematological diseases, usually persisting in the blood, lymphoma and/or bone marrow, render surgical and local treatments for solid tumors clinically ineffective. The presence and resistance of cancer stem cells (CSC) further make them difficult to cure. The development of new personalized therapies, such as molecularly targeted drugs, monoclonal and bispecific antibodies and CART-T cells, has improved the clinical outcome of lymphoproliferative diseases. This Special Issue, entitled "Challenges and Therapeutic Prospects in Hematology Oncology", aims to update clinical aspects of hematologic malignancies, such as lymphoma, leukemia and multiple myeloma, with research articles as well as comprehensive review papers addressing the state of the art and the future perspectives of hematologic malignancies, focusing preferentially on innovative research in diagnosis, prognosis and personalized therapy.

Guest Editor

Dr. Magdalena Witkowska

Department of Experimental Hematology, Medical University of Lodz,
93-510 Lodz, Poland

Deadline for manuscript submissions

closed (10 December 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/174220

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).